News

The companies, under the licensing and Cooperative Research and Development Agreements (CRADA) will also develop a technology platform based on NCI’s cancer vaccine technology. In addition, Bavarian Nordic

Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. Neratinib is being studied in the

The new partnership includes recruitment and development of contract sales force specializing in medical food sales for lead therapeutic, Vascazen, a therapeutic by Pivotal. Pivotal Therapeutics president Rachelle

The research company will receive $11.7m for toxicology studies and an additional $2.6 m for pharmacology and pharmacokinetics studies which will be conducted through NCI’s Developmental Therapeutics Program.

The product, Mdrive comprises a blend of bio-active extracts from plants, roots, herbs and mushrooms which are scientifically formulated to support the adrenal gland besides increasing testosterone levels,.

As per the new deal, Agios will receive a $20m payment and Celgene will have exclusive option to drug candidates generated by Agios’ cancer metabolism research platform during

Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties. The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 patients with relapsing forms of MS and showed

The GRF peptide is said to have the similar potency and efficacy as that of tesamorelin and is shorter than it. Tesamorelin is an analogue of the human

The trial will evaluate the efficacy of BioCancell’s BC-819 in sequence with Gemcitabine, in treating locally-advanced, unresectable pancreatic cancer. pbpb About 100 participants are expected to be enrolled